Clin Osteol 2019; 24(2): 69-73

Prevention and treatment of osteoporosis: causal or symptomatic?Review articles

Štěpán Jan
Revmatologický ústav a 1. LF UK, Praha

The severity of the health and socio-economic consequences of osteoporosis in women and in men increases with increasing life expectancy and the ageing of the population. The potential to reduce these risks is with causal measures. Syndrome of osteoporosis represents clinical manifestation of aging (involutional osteoporosis) and chronic diseases (secondary osteoporosis). In subjects with involutional bone loss, the physical activity and low inflammatory index diet appears an effective causal measure in the prevention of osteoporosis and fractures. In secondary osteoporosis, an effective first-line option is treatment of the underlying disease; during early postmenopause hormonal therapy or selective estrogen receptor modulators should be considered. Otherwise, in people with significantly high fracture risk, symptomatic antiresorptive or bone anabolic therapy is available.

Keywords: fracture risk; involutional osteoporosis; prevention of osteoporosis; secondary osteoporosis; treatment of osteoporosis

Received: June 28, 2019; Accepted: July 2, 2019; Published: December 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jan Š. Prevention and treatment of osteoporosis: causal or symptomatic? Clinical Osteology. 2019;24(2):69-73.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Svedbom A, Hernlund E, Ivergård M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8 : 137. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657-013-0137-0>. Go to original source...
    2. Eastell R, Rosen CJ, Black DM et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019; 104(5):1595-1622. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2019-00221>. Go to original source...
    3. Lindsay R, Krege JH, Marin F et al. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int 2016; 27(8): 2395-2410. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-016-3534-6>. Go to original source...
    4. Fuksa L, Vytrisalova M. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Curr Med Res Opin 2015; 31(9): 1645-1653. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2015.1065241>. Go to original source...
    5. Hiligsmann M, Rabenda V, Gathon HJ et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86(3): 202-210. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223-009-9329-4>. Go to original source...
    6. Piemontese M, Almeida M, Robling AG et al. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight 2017; 2(17).pii: 93771. Dostupné z DOI: <http://dx.doi.org/10.1172/jci.insight.93771>. Go to original source...
    7. Watson SL, Weeks BK, Weis LJ et al. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: The LIFTMOR randomized controlled trial. J Bone Miner Res 2018; 33(2): 211-220. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3284>. Erratum in High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. [J Bone Miner Res 2019]. Go to original source...
    8. Mikkelsen UR, Couppe C, Karlsen A et al. Life-long endurance exercise in humans: circulating levels of inflammatory markers and leg muscle size. Mech Ageing Dev 2013; 134(11-12): 531-540. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mad.2013.11.004>. Go to original source...
    9. Nilsson M, Sundh D, Mellstrom D et al. Current physical activity is independently associated with cortical bone size and bone strength in elderly Swedish women. J Bone Miner Res 2017; 32(3): 473-485. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3006>. Go to original source...
    10. Benetou V, Orfanos P, Feskanich D et al. Mediterranean diet and hip fracture incidence among older adults: the CHANCES project. Osteoporos Int 2018; 29(7): 1591-1599. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-018-4517-6>. Go to original source...
    11. Sahota O, Mundey MK, San P et al. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 2004; 35(1) :312-319. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2004.02.003>. Go to original source...
    12. Sakuma M, Endo N, Oinuma T et al. Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int 2006; 17(11): 1608-1614. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-006-0167-1>. Go to original source...
    13. Lips P, Cashman KD, Lamberg-Allardt C et al. Management of endocrine disease: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. Eur J Endocrinol 2019. pii: EJE-18-0736.R1. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-18-0736>. Go to original source...
    14. Zittermann A, Prokop S, Gummert JF et al. Safety issues of vitamin D supplementation. Anticancer Agents Med Chem 2013; 13(1): 4-10. Go to original source...
    15. Jaaskelainen T, Itkonen ST, Lundqvist A et al. The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. Am J Clin Nutr 2017; 105(6):1512-1520. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.116.151415>. Go to original source...
    16. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3):321-333. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.288.3.321>. Go to original source...
    17. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291(14):1701-1712. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.291.14.1701>. Go to original source...
    18. Cauley JA. The Women's Health Initiative: Hormone therapy and calcium/vitamin D supplementation trials. Curr Osteoporos Rep 2013; 11(3):171-178. Dostupné z DOI: <http://dx.doi.org/10.1007/s11914-013-0150-7>. Go to original source...
    19. Zhu L, Jiang X, Sun Y et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 2016; 23(4): 461-470. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000519>. Go to original source...
    20. Abdi F, Mobedi H, Bayat F et al. The effects of transdermal estrogen delivery on bone mineral density in postmenopausal women: A meta-analysis. Iran J Pharm Res 2017; 16(1):380-389.
    21. Bagger YZ, Tanko LB, Alexandersen P et al et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34(4): 728-735. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2003.12.021>. Go to original source...
    22. Eghbali-Fatourechi G, Khosla S, Sanyal A et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111(8):1221-1230. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI17215>. Go to original source...
    23. Eriksen EF, Langdahl B, Vesterby A et al. Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. J Bone Miner Res 1999; 14(7): 1217-1221. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.1999.14.7.1217>. Go to original source...
    24. Collins BC, Laakkonen EK, Lowe DA. Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength. Bone 2019; 123 : 137-144. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2019.03.033>. Go to original source...
    25. Oestergaard S, Sondergaard BC, Hoegh-Andersen P et. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006; 54(8): 2441-2451. Dostupné z DOI: <http://dx.doi.org/10.1002/art.22009>. Go to original source...
    26. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166(3) :357-365. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.166.3.357>. Go to original source...
    27. Boardman HM, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; (3):CD002229. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD002229.pub4>. Go to original source...
    28. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2018; 25(11): 1362-1387. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000001241>.
    29. Baber RJ, Panay N, Fenton A et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016; 19(2): 109-150. Dostupné z DOI: <http://dx.doi.org/10.3109/13697137.2015.1129166>. Go to original source...
    30. Stuenkel CA, Davis SR, Gompel A et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100(11): 3975-4011. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015-2236>. Go to original source...
    31. Manson JE, Ames JM, Shapiro M et al. Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society. Menopause 2015; 22(3): 247-253. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000373>. Go to original source...
    32. Štěpán J, Rosa J, Pavelka K. Raloxifen -⁠ nevyužitá možnost prevence a léčby postmenopauzální osteoporózy. Vnitr Lek 2016; 62(10): 781-788.
    33. Eller-Vainicher C, Falchetti A, Gennari L et al. Diagnosis of endocrine disease: Evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019.pii: EJE-18-0991.R1. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-18-0991>. Go to original source...
    34. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89(2): 503-510. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2003-031110>. Go to original source...
    35. Gough AK, Lilley J, Eyre S et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344(8914): 23-27. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140-6736(94)91049-9>. Go to original source...
    36. Haugeberg G, Helgetveit KB, Forre O et al. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 2014; 15 : 289. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2474-15-289>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.